Bli medlem
Bli medlem

Du är här

2016-03-11

Bionor Pharma ASA: Updated Financial Calendar 2016

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Updated Financial Calendar 2016

(Oslo, Norway, 11 March 2016) Bionor Pharma ASA (OSE:BIONOR) has changed the
date for the publication of the Annual Report 2015 and now scheduled its
financial calendar for the remainder of 2016 as follows:

31 March 2016 - Annual Report 2015
21 April 2016 - Annual General Meeting
11 May 2016 - Q1 2016 Interim Financial Report
23 August 2016 - Q2 2016 Interim Financial Report
16 November 2016 - Q3 2016 Interim Financial Report

The dates may be subject to change.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information

Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39
03,jfr@bionorpharma.com

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by reducing latent HIV reservoir and further demonstrated
control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available
atwww.bionorpharma.com.

Updated Financial Calendar 2016
http://hugin.info/131219/R/1993762/734075.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#1993762

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.